Guidelines: Difference between revisions

(7 intermediate revisions by the same user not shown)

Line 5:

==== Prostate ====

* ~~'''NEW!'''~~ [[AUA & ASTRO & SUO: Salvage Therapy for Prostate Cancer (2024)|Salvage Therapy for Prostate Cancer (2024)]]

* [[AUA & ASTRO & SUO: Salvage Therapy for Prostate Cancer (2024)|Salvage Therapy for Prostate Cancer (2024)]]

* [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]]

*[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]]

Line 17:

* '''NEW!''' [[Microscopic Hematuria (2025)]]

* '''NEW!''' [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2024 AUA)|Non-muscle Invasive Bladder Cancer (2024)]]

* ~~'''NEW!'''~~ [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2024)|Muscle-invasive Bladder Cancer (2024)]]

* [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2024)|Muscle-invasive Bladder Cancer (2024)]]

*[[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]]

*[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]]

Line 46:

==== Functional ====

* '''NEW!''' [[Incontinence after Prostate Therapy (2024)]]

* [[AUA: Overactive Bladder (2019)|Overactive Bladder (2024)]]

* [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]]

*[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]]

*'''NEW!''' [[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]]

*[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]]

* [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]]

Line 74:

Line 75:

* [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]]

*~~'''NEW!'''~~ [[AUA: Interstitial Cystitis & Bladder Pain Syndrome (2022)|Interstitial Cystitis/Bladder Pain Syndrome (2022)]]

*[[AUA: Interstitial Cystitis & Bladder Pain Syndrome (2022)|Interstitial Cystitis/Bladder Pain Syndrome (2022)]]

*[[AUA: Urotrauma (2020)|Urotrauma (2020)]]

* [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]]

Line 81:

Line 82:

==== Contribute ====

* Overactive Bladder (2024)

* Incontinence after Prostate Therapy (2024 Amendment)

*Incontinence after Prostate Therapy ~~(2024 Amendment)~~

*Non-muscle Invasive Bladder Cancer (2024 Amendment)

*Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)

*Management of LUTS attributed to BPH (2023 Amendment)

Line 113:

Line 112:

==== Kidney ====

* '''NEW!''' [[CUA: Cystic Renal Lesions (2023)|Cystic Renal Lesions (2023)]]

* [[CUA: Follow-up Localized RCC (2018)|Follow-up Localized RCC (2018)]]

* [[CUA: Cystic Renal Lesions (2017)|Cystic Renal Lesions (2017)]]

@@ Line 5: / Line 5: @@
 ==== Prostate ====
-* '''<span style="color:#008000">NEW!</span>''' [[AUA & ASTRO & SUO: Salvage Therapy for Prostate Cancer (2024)|Salvage Therapy for Prostate Cancer (2024)]]
+* [[AUA & ASTRO & SUO: Salvage Therapy for Prostate Cancer (2024)|Salvage Therapy for Prostate Cancer (2024)]]
 * [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]]
 *[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]]
@@ Line 17: / Line 17: @@
 * '''<span style="color:#008000">NEW!</span>''' [[Microscopic Hematuria (2025)]]
 * '''<span style="color:#008000">NEW!</span>''' [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2024 AUA)|Non-muscle Invasive Bladder Cancer (2024)]]
-* '''<span style="color:#008000">NEW!</span>''' [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2024)|Muscle-invasive Bladder Cancer (2024)]]
+* [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2024)|Muscle-invasive Bladder Cancer (2024)]]
 *[[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]]
 *[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]]
@@ Line 46: / Line 46: @@
 ==== Functional ====
+* '''<span style="color:#008000">NEW!</span>''' [[Incontinence after Prostate Therapy (2024)]]
+* [[AUA: Overactive Bladder (2019)|Overactive Bladder (2024)]]
 * [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]]
 *[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]]
-*'''<span style="color:#008000">NEW!</span>''' [[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]]
 *[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]]
 * [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]]
@@ Line 74: / Line 75: @@
 * [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]]
-*'''<span style="color:#008000">NEW!</span>''' [[AUA: Interstitial Cystitis & Bladder Pain Syndrome (2022)|Interstitial Cystitis/Bladder Pain Syndrome (2022)]]
+*[[AUA: Interstitial Cystitis & Bladder Pain Syndrome (2022)|Interstitial Cystitis/Bladder Pain Syndrome (2022)]]
 *[[AUA: Urotrauma (2020)|Urotrauma (2020)]]
 * [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]]
@@ Line 81: / Line 82: @@
 ==== Contribute ====
-* Overactive Bladder (2024)
+* Incontinence after Prostate Therapy (2024 Amendment)
-*Incontinence after Prostate Therapy (2024 Amendment)
-*Non-muscle Invasive Bladder Cancer (2024 Amendment)
 *Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
 *Management of LUTS attributed to BPH (2023 Amendment)
@@ Line 113: / Line 112: @@
 ==== Kidney ====
+* '''<span style="color:#008000">NEW!</span>''' [[CUA: Cystic Renal Lesions (2023)|Cystic Renal Lesions (2023)]]
 * [[CUA: Follow-up Localized RCC (2018)|Follow-up Localized RCC (2018)]]
 * [[CUA: Cystic Renal Lesions (2017)|Cystic Renal Lesions (2017)]]